The increased AAT levels in the plasma of subjects with severe SARS-CoV-2-ARDS or nsARDS was regulated largely by circulating IL-6, as shown by in vitro and in vivo inhibition with tocilizumab (Figures 5 a,b,c and 6a). Here, IL6 is linked to acute respiratory distress syndrome.